文献速递烧伤创面修复

拓展酶性清创边界:NexoBrid在急性烧伤中标签内与超标签应用的短期实验室及代谢反应

Expanding the boundaries of enzymatic debridement: Short-term laboratory and metabolic responses to on-label and off-label NexoBrid application in acute burn care.
PubMed 文献 · Burns · 2026-08-18

回顾性单中心队列纳入167例接受NexoBrid治疗的成人烧伤患者,按治疗面积≤15%TBSA(标签内,n=110)与>15%TBSA(超标签,n=57)分组,比较基线至应用后3-4天的实验室与代谢指标。超标签组烧伤面积更大(平均TBSA 35% vs 14%)、死亡率更高(17.9% vs 13%)。电解质变化为一过性(钾暂升、钙暂降),代谢指标稳定,血红蛋白和血细胞比容显著下降且超标签组更明显,但无持续乳酸升高或重大短期代谢紊乱。

要点

  • 超标签组(>15%TBSA)烧伤面积更大、死亡率更高,但未见重大短期电解质或代谢紊乱。
  • 电解质变化为一过性(钾暂升、钙暂降),迅速恢复正常且无临床意义。
  • 血红蛋白和血细胞比容显著下降,超标签组更明显,可能反映烧伤严重程度而非酶清创直接效应。

核心结论

  • 在本回顾性队列中,包括超标签(治疗面积>15%TBSA)应用在内,酶性清创后未观察到重大短期电解质或代谢紊乱。
  • 观察到的血液学下降可能反映整体烧伤严重程度,而非治疗特异性效应。
  • 两组间烧伤严重程度差异大且缺乏非NexoBrid对照队列,无法就整体系统安全性得出因果结论。

研究设计与样本

  • 回顾性单中心队列研究,纳入2020至2024年间接受NexoBrid治疗的167例成人烧伤患者。
  • 按治疗面积分为标签内组(≤15%TBSA,n=110)和超标签组(>15%TBSA,n=57)。
  • 分析基线至应用后3-4天预设时间点的电解质、pH、碱剩余、乳酸、血红蛋白和血细胞比容。

主要发现

  • 超标签组烧伤面积更大(平均TBSA 35% vs 14%),死亡率更高(17.9% vs 13%)。
  • 电解质变化为一过性:钾暂时升高、钙暂时降低,均迅速恢复正常且无临床相关性。
  • 代谢参数保持稳定,碱剩余改善,无持续乳酸升高。
  • 血红蛋白和血细胞比容随时间显著下降,超标签组更明显,与烧伤严重程度和治疗范围一致。

临床怎么用

  • 超标签(>15%TBSA)应用NexoBrid后短期内未见重大电解质或代谢紊乱,可关注但不必过度担忧。
  • 应用后血红蛋白和血细胞比容下降更可能反映烧伤严重程度,应结合整体病情评估而非归因于酶清创。
  • 需警惕两组烧伤严重程度差异带来的混杂,不能据此推断整体系统安全性。

局限性

  • 回顾性单中心设计。
  • 两组间烧伤严重程度存在显著差异。
  • 缺乏非NexoBrid对照队列,无法进行因果推断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Enzymatic debridement with NexoBrid® is increasingly used beyond current label restrictions, particularly in patients with extensive burns. However, data on systemic safety and metabolic effects in large-area applications remain limited. This study aimed to evaluate short-term laboratory and metabolic changes following on-label and off-label use. METHODS: In this retrospective single-center cohort study, 167 adult burn patients treated with NexoBrid between 2020 and 2024 were included. Patients were stratified into on-label (≤15% TBSA treated, n = 110) and off-label (>15% TBSA treated, n = 57) groups. Laboratory parameters including electrolytes, pH, base excess, lactate, hemoglobin, and hematocrit were analyzed at predefined time points from baseline to day 3-4 post-application. RESULTS: Off-label patients had significantly larger burns (mean TBSA 35% vs. 14%) and higher mortality (17.9% vs. 13%). Electrolyte changes were transient, with a temporary increase in potassium and decrease in calcium, both normalizing rapidly without clinical relevance. Metabolic parameters remained stable, with improving base excess and no sustained lactate elevation. In contrast, hemoglobin and hematocrit decreased significantly over time, more pronounced in the off-label group, consistent with burn severity and treatment extent rather than a direct effect of enzymatic debridement. CONCLUSIONS: In this retrospective cohort, no major short-term electrolyte or metabolic derangements were observed following enzymatic debridement, including patients undergoing off-label (>15% TBSA treated) treatment. The observed hematologic decline likely reflects overall burn severity rather than a treatment-specific effect. However, substantial differences in burn severity between groups and the absence of a non-NexoBrid control cohort preclude causal conclusions regarding overall systemic safety.

来源:Burns,查看原文。版权归原作者所有。

引用

  1. Schmidt SV, Alekos C, Drysch M, et al. Expanding the boundaries of enzymatic debridement: Short-term laboratory and metabolic responses to on-label and off-label NexoBrid application in acute burn care. Burns. 2026. PMID: 42854441. doi:10.1016/j.burns.2026.108182

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。